Skip to main content

Table 1 Transcriptomic and proteomic classifiers of triple negative breast cancer

From: Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications

TNBC
Classifier
Year Number of TNBC cases Subtypes Biological level information Key clinical findings
Transcriptomic profiling
Lehmann et al.[4]
Lehmann et al. [57]
2011
Refined in
2016
587 6 main subtypes:
Basal-like 1
Basal-like 2 Immunomodulatory
Luminal androgen receptor
Mesenchymal
Mesenchymal stem-like
RNA expression Basal-like 1 had a higher pathologic complete response rate after neoadjuvant chemotherapy and a better overall survival
    4 main subtypes:
Basal-like 1
Basal-like 2
Luminal androgen receptor
Mesenchymal
  
Burstein et al. [7] 2015 198 4 main subtypes:
Basal-like immune activated
Basal-like immune suppressed
Luminal androgen receptor
Mesenchymal
RNA expression and DNA copy number Four clinically distinct subtypes
Survival outcomes were most favorable for basal-like immune activated
and worst for basal-like immune suppressed
Jiang et al.[6] 2019 504 4 main subtypes:
Immunomodulatory
Basal-like immune suppressed
Luminal androgen receptor
Mesenchymal
RNA expression, DNA copy number and somatic mutations Distinct patterns related to the Chinese TNBC population: higher frequencies of PIK3CA mutations and luminal androgen receptor subtype
Basal-like immune suppressed with high-homologous recombination deficiency scores had a better prognosis when compared to those with low scores
Bareche et al. [35] 2018 550 5 main subtypes:
Basal-like 1
Immunomodulatory
Luminal androgen receptor
Mesenchymal
Mesenchymal stem-like
RNA expression, DNA copy number and somatic mutations Immunomodulatory subtype was significantly associated with a better prognosis
Luminal androgen receptor
and mesenchymal stem-like subtypes were associated with low grade tumors
Proteomic profiling
Gong et al. [76] 2022 90 fresh- frozen 4 main subtypes
Immunomodulatory
Basal-like immune suppressed
Luminal androgen receptor
Mesenchymal
Global proteomics and phospho-proteomics
RNA expression, DNA copy number and somatic mutations
Four clinically distinct subtypes
The proteome subtype that resembled immunomodulatory had the best survival
while the proteome subtype that resembled luminal androgen receptor had the worst survival
Potential therapeutic targets involved in fatty acid metabolism (e.g. FASN) specifically for the proteome subtype that resembled luminal androgen receptor
A potential therapeutic target of NAE1 for the proteome subtype that resembled basal-like immune suppressed
Asleh et al. [60] 2022 88 Formalin- fixed paraffin-
embedded
4 main subtypes:
Basal-like immune activated
Basal-like immune suppressed
Luminal androgen receptor
Mesenchymal
Global proteomics Four clinically distinct subtypes
Survival outcomes were most favorable for the proteome subtype that resembled basal-like immune activated
and worst for basal-like immune suppressed
Potential therapeutic targets involved in antigen presentation (e.g., TAP1, HLA-DQA1) for the proteome subtype that resembled basal-like immune activated
Potential therapeutic targets involved in fatty acid metabolism (e.g., FASN) for the proteome subtype that resembled luminal androgen receptor
  1. Abbreviations: TNBC triple negative breast cancer